The BRAIN Act (S.1330) packages several targeted interventions to speed brain tumor research and improve patient access to specialized care. It directs NIH to make information about NIH-funded brain tumor biospecimens publicly discoverable, establishes new multi-institutional research programs for glioblastoma and cellular immunotherapy, funds public outreach on clinical trials and biomarker testing, supports pilot survivorship programs, and asks FDA to issue guidance to reduce unnecessary trial exclusions for brain tumor patients.
For research managers and compliance officers, the bill creates discoverability expectations for specimen holders and new grant programs that steer federal dollars toward coordinated, multi-site translational work. For clinicians and patient advocates it attempts to remove practical barriers to trial enrollment and to improve care planning for survivors; for NIH and FDA it creates specific new tasks and oversight responsibilities that will require administrative capacity and coordination across agencies.
At a Glance
What It Does
Requires NIH to host a publicly searchable catalog of NIH-funded brain tumor biospecimens and to require reporting from entities that hold such samples; creates competitive, multi-institutional research award mechanisms focused on glioblastoma and cellular immunotherapy; funds a national outreach campaign and demonstration projects on cancer clinical trials and biomarker testing; authorizes pilot programs to develop survivorship care models; and directs FDA to publish guidance to limit inadvertent exclusion of brain tumor patients from trials.
Who It Affects
Academic and hospital biorepositories that hold NIH-funded brain tumor specimens, NCI and other NIH institutes that manage cooperative awards, research consortia that seek U-series or U19 funding, clinical trial sponsors and sites, community and specialty clinicians caring for brain tumor patients, and patient/caregiver education programs.
Why It Matters
The bill tackles three common bottlenecks at once: discoverability of scarce biospecimens, fragmented early-stage translational efforts, and low patient enrollment/awareness for trials and biomarker-driven care. That combination makes it relevant to research administrators, clinical trial operations, and health system leaders planning survivorship services.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill defines a covered brain-tumor biospecimen as any tumor tissue, cerebrospinal fluid, or similar sample collected in whole or in part with NIH funding. It directs NIH leadership to make information about such collections searchable and reachable by the public, including where collections exist and whom to contact.
The core aim is to reduce duplication and enable investigators to find and request existing materials instead of re-collecting them.
On the research side, the measure creates two distinct NIH-supported pathways designed for coordinated, multi-institutional work. One is a glioblastoma-focused network built around collaborative awards intended to shepherd therapeutic candidates from pre-clinical work into early-phase human testing.
The other supports multi-site programs concentrated on cellular immunotherapies—such as CAR-T—for both adult and pediatric brain tumors, emphasizing team science across institutions. Both pathways are structured to encourage shared protocols, pooled data, and coordinated clinical translation rather than isolated single-site projects.The bill also invests in demand-side barriers to trial participation.
It tasks HHS with a national outreach effort to educate clinicians, patients, and caregivers about the role of clinical trials and biomarker testing in cancer care, and funds demonstration projects to test outreach and education strategies targeted at populations with historically low trial participation. Separately, NIH grant programs are authorized to pilot models for long-term monitoring and multidisciplinary survivorship care, including tools to ease transitions from oncology teams to primary care and to disseminate survivorship best practices.Finally, the bill asks FDA to produce guidance aimed at minimizing the unintended exclusion of brain tumor patients (including those with rare or recalcitrant cancers) from clinical trials for other indications.
The guidance is intended to clarify when and how trial eligibility criteria can be structured to avoid unnecessarily barring these patients while still protecting safety and data integrity.
The Five Things You Need to Know
Existing holders of NIH-funded brain tumor biospecimens must submit collection information to NIH within 180 days of the law’s enactment; holders who acquire new covered specimens must report them within 60 days of acquisition.
The bill authorizes $50 million per year (fiscal years 2026–2030) to fund a coordinated Glioblastoma Therapeutics Network using a U19-style cooperative mechanism.
It authorizes $10 million per year (fiscal years 2026–2030) to support multi-institutional cellular immunotherapy programs (including CAR-T) for adult and pediatric brain tumors.
Congress authorizes $10 million across fiscal years 2026–2030 for a national cancer clinical trials and biomarker-testing awareness campaign and demonstration projects, and separately authorizes $5 million per year (fiscal years 2026–2030) for survivorship pilot programs.
NIH is given an oversight tool that can be used to withhold NIH funding from entities that repeatedly or egregiously fail to comply with the biospecimen reporting requirements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Public catalog and reporting for NIH-funded brain tumor biospecimens
This provision creates the legal hook for NIH to operationalize a specimen registry: it specifies what counts as a covered biospecimen and directs NIH to make collection descriptions and contact details publicly accessible. Practically, repositories that previously treated cataloging as optional will need intake workflows to extract and transmit standardized metadata. The statute also builds in an enforcement lever: NIH must design an oversight process that can escalate repeat or severe noncompliance to funding consequences, which will require coordination between program officers, grants management, and legal counsel.
New multi-institutional research awards for glioblastoma and cellular immunotherapy
Congress sets up two parallel funding tracks aimed at bridging pre-clinical work to early-phase trials through collaborative networks. The use of U19 and U-series cooperative mechanisms signals an expectation of sustained, coordinated grant relationships rather than one-off R01 projects. For institutions, this changes proposal strategy: applications must present consortium governance, shared SOPs for translational studies, and plans for pooled data and specimen use. NIH will need to align peer review criteria to favor team science, and awardees should expect deliverables around standardization and intersite operating procedures.
Awareness campaign plus demonstration grants to increase trial and biomarker participation
This section packages a federal communication campaign with grant-funded pilots testing outreach models. The campaign must produce culturally and linguistically appropriate materials and target high-risk and underrepresented communities, while demonstration projects will compare evidence-based strategies for reaching patients, clinicians, and payers. Applicants for the demonstration awards must show partnerships that connect clinicians, academic centers, and community stakeholders; reviewers will favor applicants that demonstrate measurable links to provider networks and practical pathways to increase trial referrals.
Survivorship pilots to develop and evaluate long-term care models
NIH may fund a range of pilot projects—across medical schools, children’s hospitals, cancer centers and community sites—to test monitoring and transitional-care models for brain tumor survivors. The statutory list of allowable activities includes multidisciplinary care designs, psychosocial programs, and tools (including AI-enabled tools) to securely transfer treatment summaries to non-oncology providers. Awardees should plan for implementation research components and dissemination strategies so successful pilots can be scaled or adopted by other health systems.
FDA guidance to reduce unnecessary clinical trial exclusions
Rather than changing FDA approval standards, this provision directs the agency to clarify how trial eligibility criteria can be structured to avoid funneling brain tumor patients out of trials for other conditions. The guidance is likely to influence sponsor protocol development and institutional review board (IRB) decisions by offering risk-based approaches to eligibility and safety monitoring for such patients, and it may stimulate sponsors to reconsider blanket exclusions that have limited enrollment historically.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Investigators seeking scarce brain tumor materials — easier discovery of existing NIH-funded specimens can lower collection costs and speed preclinical research by directing researchers to existing repositories and contacts.
- Multi-institutional consortia and translational researchers — new U19/U-series pathways prioritize team science and provide a stable funding stream for coordinated preclinical-to-early-phase work that single-site grants often cannot support.
- Patients and caregivers — targeted awareness campaigns and demonstration projects aim to increase enrollment in clinical trials and access to biomarker testing, potentially widening treatment options for underrepresented groups.
- Clinicians treating survivors — survivorship pilots and dissemination requirements create tested models and tools (including care summaries) that make transitions to primary and specialty post-treatment care more practical.
- Patient advocacy organizations — the public catalog and outreach programs provide clearer pathways for advocacy groups to identify biospecimen holders, promote trial participation, and participate in demonstration projects.
Who Bears the Cost
- Small and informal biorepositories — entities that hold NIH-funded samples must invest staff time to extract metadata and comply with reporting processes, which can be nontrivial for under-resourced collections.
- NIH administrative units and peer review panels — implementing public registries, new cooperative award programs, oversight mechanisms, and demonstration/pilot grant reviews increases agency operational workload without dedicated permanent staffing in the text.
- Clinical trial sponsors and sites — while not directly charged by the bill, sponsors may need to revise eligibility criteria and monitoring approaches in response to FDA guidance, potentially complicating protocol design and safety monitoring.
- Hospitals and health systems participating in pilots — deploying survivorship models, secure transfer tools, or AI-assisted summaries will require IT integration, staff training, and care coordination investments.
- State agencies and community-based organizations — outreach and culturally competent engagement envisioned by the bill may require community partners to expand capacity to receive and act on increased patient referrals.
Key Issues
The Core Tension
The central dilemma is balancing more transparent, searchable biospecimen information and centralized, well-funded translational networks against the burdens those requirements impose on small repositories and on NIH/FDA administrative capacity: increasing access and coordination can accelerate research, but only if the registry, standards, enforcement approach, and funding priorities are implemented in ways that protect donor privacy, support under-resourced partners, and do not inadvertently narrow the research agenda.
The bill mixes disclosure, directed funding, and soft regulatory action; each element raises practical trade-offs. Making NIH-funded biospecimen holdings publicly discoverable improves research efficiency but creates compliance and privacy questions.
Repositories will need to supply standardized metadata and contact points, yet the statute does not prescribe data standards, access conditions, or protections for sensitive donor information—leaving significant implementation choices to NIH. Those choices will determine whether the catalog actually facilitates sample sharing or creates an administrative checklist that strains small collections.
Targeting large sums to glioblastoma networks and multi-institutional cellular immunotherapy programs is a deliberate concentration of federal support, but it may crowd out more diffuse investigator-initiated research or other brain tumor subtypes not explicitly prioritized. Demonstration projects and survivorship pilots emphasize dissemination, yet the bill omits sustained implementation funding or explicit scaling pathways for successful pilots.
Finally, the statutory oversight power to withhold NIH funds for noncompliance gives NIH leverage, but absent clear graduated enforcement steps it risks imposing disproportionate penalties on smaller actors who lack administrative infrastructure rather than on willful bad actors.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.